Aster DM Quality Care (ASTERDM) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
26 Aug, 2026Executive summary
The merger of Aster DM Healthcare and Quality Care, effective July 1, 2026, created a top 3 hospital chain in India with 39 hospitals and over 10,800 beds, executed with strong cultural integration and zero operational friction.
The combined entity demonstrates strong year-on-year revenue growth, operational leverage, and improved margins, driven by increased patient volumes, specialty mix, and digital health initiatives.
Strategic priorities include scaling super-specialty care, expanding into Tier 2 and Tier 3 cities, and driving patient-centric innovation.
The merger was sanctioned by NCLT and included a name change, with auditors expressing an unmodified review conclusion on the unaudited results.
Backed by Blackstone, the merger aims for scale, enhanced metrics, synergies, diversification, and long-term value creation.
Financial highlights
Q1 FY 2027 pro forma revenue rose 20% year-on-year to INR 2,597 crore; EBITDA grew 30% to INR 576 crore, with margin expanding 170 bps to 22.2%.
Mature units contributed 73% of revenue, growing 19% year-on-year; emerging units saw up to 95% revenue growth and 240% EBITDA growth.
Net debt at the combined level is INR 1,162 crore as of June 30, 2026.
Normalised PAT (post NCI) for Aster grew 39% YoY to INR 125 crore in Q1 FY 2027.
Exceptional merger-related costs impacted net profit, with consolidated net profit at INR 29.28 crore and standalone net loss at INR 14.30 crore.
Outlook and guidance
Management maintains guidance of achieving 24%-25% EBITDA margin within two to three years post-merger, targeting FY 2028-2029.
Synergy realization is expected to deliver 10%-15% incremental EBITDA based on FY 2024 pro forma, with significant benefits anticipated from scale and operational integration.
Planned expansion to add over 4,170 beds, targeting 15,077 total beds by FY30, with 53% in existing and 47% in new facilities.
Medical Value Travel (MVT) is targeted to reach double-digit revenue contribution, with growth rates above 50%.
Ongoing investments in subsidiaries and associates support strategic growth.
Latest events from Aster DM Quality Care
- Aster DM and QCIL merge to form a top 3 Indian hospital chain with 10,150+ beds and strong growth.ASTERDM
Investor Presentation - Strong growth in revenue, capacity, and clinical excellence, with major expansion plans ahead.ASTERDM
Investor Presentation - Merger with QCIL positions the group among India's top 3 hospital chains by scale and revenue.ASTERDM
Investor presentation - 15% YoY revenue and 22% EBITDA growth, merger progress, and internal restructuring marked Q3FY26.ASTERDM
Q3 25/26 - Q2 FY26 delivered strong growth, margin expansion, hospital launches, and QCL merger progress.ASTERDM
Q2 25/26 - Merger forms a top-three Indian hospital chain with 10,150+ beds, strong synergies, and Blackstone backing.ASTERDM
M&A Announcement - Double-digit revenue and profit growth, margin expansion, and strong outlook in H1 FY25.ASTERDM
Q2 24/25 - Record net profit and EPS in Q1 FY25, driven by GCC business sale and strong India growth.ASTERDM
Q1 24/25 - FY25 revenue up 12%, EBITDA margin at 19.5%, QCIL merger and major one-time gains boost results.ASTERDM
Q4 24/25